vs
布鲁克（BRKR）与Cytek Biosciences, Inc.（CTKB）财务数据对比。点击上方公司名可切换其他公司
布鲁克的季度营收约是Cytek Biosciences, Inc.的15.7倍（$977.2M vs $62.1M）。布鲁克净利率更高（2.7% vs -70.9%，领先73.6%）。Cytek Biosciences, Inc.同比增速更快（8.1% vs -0.2%）。布鲁克自由现金流更多（$207.2M vs $-1.8M）。过去两年Cytek Biosciences, Inc.的营收复合增速更高（17.7% vs 16.4%）
布鲁克公司是美国科学仪器制造商，总部位于马萨诸塞州比勒里卡，为公开上市企业。公司产品服务于分子与材料研究、工业及应用分析领域，旗下设有布鲁克科学仪器、布鲁克能源与超导技术（BEST）两大业务板块。
Cytek Biosciences主营高性能流式细胞分析系统、配套试剂及分析软件的研发、生产与商业化，产品服务覆盖生命科学研究、临床诊断、生物制药开发等领域，客户遍及全球多个主要地区。
BRKR vs CTKB — 直观对比
营收规模更大
BRKR
是对方的15.7倍
$62.1M
营收增速更快
CTKB
高出8.4%
-0.2%
净利率更高
BRKR
高出73.6%
-70.9%
自由现金流更多
BRKR
多$209.0M
$-1.8M
两年增速更快
CTKB
近两年复合增速
16.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $977.2M | $62.1M |
| 净利润 | $26.0M | $-44.1M |
| 毛利率 | 46.0% | 52.9% |
| 营业利润率 | 7.8% | -9.0% |
| 净利率 | 2.7% | -70.9% |
| 营收同比 | -0.2% | 8.1% |
| 净利润同比 | 89.8% | -557.1% |
| 每股收益（稀释后） | $0.10 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BRKRCTKB
| Q4 25 | $977.2M | $62.1M | ||
| Q3 25 | $860.5M | $52.3M | ||
| Q2 25 | $797.4M | $45.6M | ||
| Q1 25 | $801.4M | $41.5M | ||
| Q4 24 | $979.6M | $57.5M | ||
| Q3 24 | $864.4M | $51.5M | ||
| Q2 24 | $800.7M | $46.6M | ||
| Q1 24 | $721.7M | $44.9M |
净利润BRKRCTKB
| Q4 25 | $26.0M | $-44.1M | ||
| Q3 25 | $-59.6M | $-5.5M | ||
| Q2 25 | $7.6M | $-5.6M | ||
| Q1 25 | $17.4M | $-11.4M | ||
| Q4 24 | $13.7M | $9.6M | ||
| Q3 24 | $40.9M | $941.0K | ||
| Q2 24 | $7.6M | $-10.4M | ||
| Q1 24 | $50.9M | $-6.2M |
毛利率BRKRCTKB
| Q4 25 | 46.0% | 52.9% | ||
| Q3 25 | 44.1% | 52.7% | ||
| Q2 25 | 44.9% | 52.3% | ||
| Q1 25 | 48.8% | 48.6% | ||
| Q4 24 | 50.4% | 58.5% | ||
| Q3 24 | 48.4% | 56.3% | ||
| Q2 24 | 48.0% | 54.6% | ||
| Q1 24 | 48.9% | 51.3% |
营业利润率BRKRCTKB
| Q4 25 | 7.8% | -9.0% | ||
| Q3 25 | -6.0% | -17.6% | ||
| Q2 25 | 1.5% | -23.3% | ||
| Q1 25 | 4.0% | -36.1% | ||
| Q4 24 | 7.4% | 5.2% | ||
| Q3 24 | 7.9% | -8.2% | ||
| Q2 24 | 6.0% | -18.3% | ||
| Q1 24 | 9.0% | -23.9% |
净利率BRKRCTKB
| Q4 25 | 2.7% | -70.9% | ||
| Q3 25 | -6.9% | -10.5% | ||
| Q2 25 | 1.0% | -12.2% | ||
| Q1 25 | 2.2% | -27.5% | ||
| Q4 24 | 1.4% | 16.8% | ||
| Q3 24 | 4.7% | 1.8% | ||
| Q2 24 | 0.9% | -22.4% | ||
| Q1 24 | 7.1% | -13.8% |
每股收益（稀释后）BRKRCTKB
| Q4 25 | $0.10 | — | ||
| Q3 25 | $-0.41 | — | ||
| Q2 25 | $0.05 | — | ||
| Q1 25 | $0.11 | — | ||
| Q4 24 | $0.09 | — | ||
| Q3 24 | $0.27 | — | ||
| Q2 24 | $0.05 | — | ||
| Q1 24 | $0.35 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $298.8M | $90.9M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $2.5B | $341.7M |
| 总资产 | $6.2B | $461.5M |
| 负债/权益比越低杠杆越低 | 0.76× | — |
8季度趋势，按日历期对齐
现金及短期投资BRKRCTKB
| Q4 25 | $298.8M | $90.9M | ||
| Q3 25 | $293.1M | $93.3M | ||
| Q2 25 | $92.0M | $75.5M | ||
| Q1 25 | $184.2M | $95.3M | ||
| Q4 24 | $183.4M | $98.7M | ||
| Q3 24 | $148.1M | $162.3M | ||
| Q2 24 | $169.7M | $177.9M | ||
| Q1 24 | $340.1M | $168.8M |
总债务BRKRCTKB
| Q4 25 | $1.9B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $1.4B | — |
股东权益BRKRCTKB
| Q4 25 | $2.5B | $341.7M | ||
| Q3 25 | $2.4B | $378.6M | ||
| Q2 25 | $1.8B | $377.6M | ||
| Q1 25 | $1.8B | $379.6M | ||
| Q4 24 | $1.8B | $395.7M | ||
| Q3 24 | $1.8B | $385.5M | ||
| Q2 24 | $1.8B | $389.1M | ||
| Q1 24 | $1.4B | $392.6M |
总资产BRKRCTKB
| Q4 25 | $6.2B | $461.5M | ||
| Q3 25 | $6.4B | $494.9M | ||
| Q2 25 | $6.3B | $493.3M | ||
| Q1 25 | $5.9B | $482.6M | ||
| Q4 24 | $5.8B | $499.5M | ||
| Q3 24 | $6.1B | $491.2M | ||
| Q2 24 | $5.9B | $483.7M | ||
| Q1 24 | $4.5B | $492.1M |
负债/权益比BRKRCTKB
| Q4 25 | 0.76× | — | ||
| Q3 25 | 0.83× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 1.18× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 1.21× | — | ||
| Q1 24 | 0.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.8M | $-771.0K |
| 自由现金流经营现金流 - 资本支出 | $207.2M | $-1.8M |
| 自由现金流率自由现金流/营收 | 21.2% | -2.9% |
| 资本支出强度资本支出/营收 | 2.3% | 1.6% |
| 现金转化率经营现金流/净利润 | 8.84× | — |
| 过去12个月自由现金流最近4个季度 | $43.3M | $-8.8M |
8季度趋势，按日历期对齐
经营现金流BRKRCTKB
| Q4 25 | $229.8M | $-771.0K | ||
| Q3 25 | $-33.2M | $-3.9M | ||
| Q2 25 | $-127.5M | $108.0K | ||
| Q1 25 | $65.0M | $-125.0K | ||
| Q4 24 | $190.0M | $2.0M | ||
| Q3 24 | $38.4M | $13.2M | ||
| Q2 24 | $1.1M | $6.2M | ||
| Q1 24 | $21.8M | $4.0M |
自由现金流BRKRCTKB
| Q4 25 | $207.2M | $-1.8M | ||
| Q3 25 | $-54.1M | $-4.6M | ||
| Q2 25 | $-148.8M | $-1.5M | ||
| Q1 25 | $39.0M | $-974.0K | ||
| Q4 24 | $153.3M | $1.1M | ||
| Q3 24 | $5.8M | $12.2M | ||
| Q2 24 | $-23.5M | $5.2M | ||
| Q1 24 | $400.0K | $3.4M |
自由现金流率BRKRCTKB
| Q4 25 | 21.2% | -2.9% | ||
| Q3 25 | -6.3% | -8.7% | ||
| Q2 25 | -18.7% | -3.2% | ||
| Q1 25 | 4.9% | -2.3% | ||
| Q4 24 | 15.6% | 1.9% | ||
| Q3 24 | 0.7% | 23.7% | ||
| Q2 24 | -2.9% | 11.0% | ||
| Q1 24 | 0.1% | 7.6% |
资本支出强度BRKRCTKB
| Q4 25 | 2.3% | 1.6% | ||
| Q3 25 | 2.4% | 1.3% | ||
| Q2 25 | 2.7% | 3.5% | ||
| Q1 25 | 3.2% | 2.0% | ||
| Q4 24 | 3.7% | 1.6% | ||
| Q3 24 | 3.8% | 2.0% | ||
| Q2 24 | 3.1% | 2.3% | ||
| Q1 24 | 3.0% | 1.3% |
现金转化率BRKRCTKB
| Q4 25 | 8.84× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -16.78× | — | ||
| Q1 25 | 3.74× | — | ||
| Q4 24 | 13.87× | 0.21× | ||
| Q3 24 | 0.94× | 14.05× | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.43× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRKR
| Bsi Nano | $309.1M | 32% |
| Bsi Biospin | $267.0M | 27% |
| Other | $179.9M | 18% |
| Transferred Over Time | $142.5M | 15% |
| Energy And Supercon Technologies | $69.5M | 7% |
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
